PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES

Procept BioRobotics (NASDAQ: PRCT) has recently come under scrutiny after reporting a staggering adjusted EBITDA loss of $50.2 million for the fiscal year 2025, significantly diverging from the company's guidance of $35 million. This discrepancy, amounting to an unfavorable difference of $15.2 million, equates to a 43% increase in projected losses and has contributed to a decline of over 15% in the stock's value upon the announcement.

During the Q3 2025 earnings call, CFO Kevin Waters provided optimistic forecasts that painted a picture of stable financial performance. However, the reality emerged in the final figures, revealing not only the sharp increase in EBITDA losses but also a reduction in revenue, which totaled $308.1 million against a predicted $325.5 million. The company's fourth-quarter earnings per share (EPS) of -$0.53 also fell short of the analyst consensus estimate of -$0.32, marking a significant miss of 66%.

Moreover, Procept claimed stability in the average selling price of their handpieces, estimated at $3,200; however, this assertion was complicated by the elimination of prior bulk-purchase discounts that had affected actual revenue realization. In light of these discrepancies, law firm Levi & Korsinsky, LLP has initiated an investigation, urging investors who have incurred losses to explore their legal options.

The financial fallout has raised questions about the company's forecasting methods and transparency in reporting, prompting shareholder concern and potential legal action as investors seek to understand their rights following these disheartening results.

Procept BioRobotics (NASDAQ: PRCT) recently reported financial results that raised concerns among investors, most notably a $50.2 million adjusted EBITDA loss versus an expected $35 million. This unexpected shortfall has sparked significant scrutiny and led to a sharp decline in share price, dropping over 15% following the announcement.

The divergence between management’s initial guidance and the actual results raises critical questions about the company’s financial health and its ability to manage operational costs effectively. Investors had expected the company to maintain handpiece selling prices at around $3,200; however, the elimination of bulk-purchase discounts has likely contributed to lower realized pricing, exacerbating revenue discrepancies. Procept reported FY 2025 revenue of $308.1 million, significantly below the projected $325.5 million, underscoring an immediate concern over revenue generation capabilities.

For investors considering PRCT in light of this news, the key takeaway is caution. The 66% earnings per share miss compared to the analyst consensus not only highlights execution issues but may also impact future investor confidence. Legal investigations, such as those initiated by Levi & Korsinsky, may indicate a broader sentiment regarding potential misstatements or failures in corporate governance.

Investors might want to closely monitor subsequent announcements from Procept, particularly related to cost management and any adjustments in pricing strategy. If the company can clarify its path toward improved financial performance and sustainable revenue growth, there may be a potential opportunity for long-term investors. For now, it may be prudent to adopt a wait-and-see approach, as further volatility in share price may continue in response to ongoing investigations and market reactions.